Global Community

Key Assumptions & Valuation Logic: Net Asset Value (NAV) Revaluation: Baseline Q2 2026 NAV of NOK 1,429 per share is adjusted upward to reflect the implied market valuation of AI infrastructure provider Nscale at a target IPO valuation of $25B (~NOK 262.5B). Nscale Ownership Contribution: Aker’s 22.7% stake in Nscale is valued at ~NOK 59.6B (~NOK 802/share).Read more

Couche-Tard sits inside the top tenth of the TGI watchlist on the primary rank and higher still on dividend growth, with a payout ratio near ten percent. It arrived there in the same three months it agreed to acquire Poland's Żabka Group for approximately US$8.6 billion, the largest acquisition in its history, funded entirely with debt, and the first network it has promised not to absorb.Read more

Investors have recently been forced to process two very different versions of ASML. The first is a company whose demand outlook is improving fast enough for management to lift 2026 sales guidance to €43–45bn and gross-margin guidance to 54–56%.Read more

VICI’s growth may slow as travel and tourism stay uncertain, but the business still throws off a lot of cash and keeps raising its payout to shareholders. The big question is whether today’s price already reflects the risks of a casino-focused real estate owner that can be volatile in a downturn.Read more

Meta’s core apps keep throwing off huge cash, and the story says new AI tools are making its ads more useful for businesses—while WhatsApp and Threads open fresh ways to grow beyond the old Facebook model. It also flags a big bet on smart glasses and heavy spending that could pay off, but could just as easily drag on results if adoption takes longer than expected.Read more

Alibaba is often treated as just a Chinese online shopping company, but it also has a cloud business, AI products, a big fintech stake, and a web of tech investments that may not be fully reflected in how the market sees it. If its cloud and AI efforts start paying off and views on China soften, the business could be re-rated as a broader tech ecosystem rather than pure e-commerce.Read more

Right Now Reddit is sitting at $136.38. It closed at $226.17 the day before.Read more

ResMed (ASX: RMD) – 12-Month Investment Thesis (August 2026) Rating: BUY (close to Strong Buy if shares remain around current levels) 12-month Target Price: A$38–41 Estimated Upside: ~20–30% (depending on current share price) Confidence: High Investment Summary ResMed is one of the highest-quality healthcare companies listed on the ASX. Despite investor concerns around obesity drugs (GLP-1 medications such as Zepbound and Wegovy), the company’s operating performance has remained exceptionally strong.Read more

Eli Lilly’s weight-loss and diabetes drugs are already driving unusually fast growth, but the bigger twist is a next‑generation treatment still in late-stage testing that could expand the company’s reach if results hold up. The upside comes with real pressure from price cuts, tougher reimbursement rules, and the risk that future trial readouts disappoint.Read more